(Q33504409)

27 July 2017

title

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion (English)

1 reference

27 July 2017

1 reference

L Paz-Ares

1

1 reference

27 July 2017

R Kunka

2

1 reference

27 July 2017

D DeMaria

3

1 reference

27 July 2017

J Cassidy

4

1 reference

27 July 2017

M Alden

5

1 reference

27 July 2017

P Beranek

6

1 reference

27 July 2017

S Kaye

7

1 reference

27 July 2017

D Littlefield

8

1 reference

27 July 2017

D Reilly

9

1 reference

27 July 2017

S Depee

10

1 reference

27 July 2017

P Wissel

11

1 reference

27 July 2017

C Twelves

12

1 reference

27 July 2017

P O'Dwyer

13

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

British Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

78

1 reference

27 July 2017

issue

10

1 reference

27 July 2017

page(s)

1329-1336

1 reference

A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

The current status of camptothecin analogues as antitumor agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Camptothecins: from bench research to hospital wards.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Reporting results of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

A model for tumor cell killing by topoisomerase poisons.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063170

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

31 October 2018

1 reference

12 December 2020

Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.679

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference